TP53 -mutant AML with ribosomal gene loss exhibits impaired protein translation and sensitivity to HSP90 inhibition
Science Advances · 15.05.2026 · 12 (20)
DOI: 10.1126/sciadv.aed7122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 15.05.2026. Verfasst von Jean-François Spinella und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Québec, Canada. Hauptthemen laut MEDLINE: HSP90 Heat-Shock Proteins, Leukemia, Myeloid, Acute, Tumor Suppressor Protein p53, Ribosomal Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Genome Canada, NanoQuébec, Canada Foundation for Innovation.
Abstract (Originalsprache)
TP53 -mutated acute myeloid leukemia (AML) represents a particularly aggressive and therapeutically refractory subtype of the disease. While recurrent chromosomal abnormalities such as -5/del(5q), -7/del(7q), and del(17p) are well studied in this context, additional co-occurring events remain less well defined. Using the multidimensional Leucegene dataset (~700 primary AML specimens), we identified and comprehensively characterized a distinct subset of TP53 -altered AML marked by recurrent deletions on the short arm of chromosome 3 [del(3p), >20% TP53 -mutated cases]. These deletions frequently co-occur with del(5q) and encompass several ribosomal protein genes (RPGs), leading to a global down-regulation of the ribosomal network and reduced protein synthesis. We show that this ribosomopathy-like phenotype is most pronounced in TP53 -mutated cases with combined RPG deletions on chromosomes 3p and 5q, suggesting a cooperative oncogenic mechanism. Chemical screening identified HSP90 inhibition as a selective vulnerability in AML with low RPG expression. These findings highlight a previously unappreciated TP53 -altered AML subset characterized by converging genomic and translational defects and suggest that ribosomal stress may serve as a therapeutic entry point for targeted intervention of this patient subgroup.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Québec, Canada.
- Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
- Leukemia Cell Bank of Quebec, Centre de recherche de l'Hôpital Maisonneuve-Rosemont, Montréal, Québec, Canada.
- Centre Hospitalier Universitaire Sainte-Justine Research Center, Montréal, Québec, Canada.
- Department of Pediatrics, Faculty of Medicine, Université de Montréal, Montréal, Québec, Canada.
- Division of Hematology-Oncology and Cell Therapy, Hôpital Maisonneuve-Rosemont Hospital, Montréal, Québec, Canada.
ORCID-Profile: Jean-François Spinella, Céline Moison, Isabel Boivin, Guillaume Richard Carpentier, Nadine Mayotte, François Béliveau, Vincent P Lavallée, Josée Hébert, Guy Sauvageau
Förderung
- Genome Canada
- NanoQuébec
- Canada Foundation for Innovation
- Canada First Research Excellence Fund
- IVADO
- the Cancer Research Network of the Fonds de recherche du Québec–Santé
- RMGA
- Fonds de recherche du Québec - Nature et technologies
Zitieren
APA
Spinella, J. F., Chagraoui, J., Moison, C., Boivin, I., Carpentier, G. R., Mayotte, N., Béliveau, F., Lavallée, V. P., Hébert, J., & Sauvageau, G. (2026). TP53 -mutant AML with ribosomal gene loss exhibits impaired protein translation and sensitivity to HSP90 inhibition. Science Advances, 12(20). https://doi.org/10.1126/sciadv.aed7122
Vancouver
Spinella JF, Chagraoui J, Moison C, Boivin I, Carpentier GR, Mayotte N, et al. TP53 -mutant AML with ribosomal gene loss exhibits impaired protein translation and sensitivity to HSP90 inhibition. Science Advances. 2026;12(20). doi:10.1126/sciadv.aed7122
BibTeX
@article{Spinella2026,
author = {Spinella, Jean-François and Chagraoui, Jalila and Moison, Céline and Boivin, Isabel and Carpentier, Guillaume Richard and Mayotte, Nadine and Béliveau, François and Lavallée, Vincent P and Hébert, Josée and Sauvageau, Guy},
title = {TP53 -mutant AML with ribosomal gene loss exhibits impaired protein translation and sensitivity to HSP90 inhibition},
journal = {Science Advances},
year = {2026},
volume = {12},
number = {20},
doi = {10.1126/sciadv.aed7122}
}
EUVIMED